NCT01336010 - Treatment of Recently Acquired Hepatitis C Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Acute Hepatitis C

Interventions

DRUG

Peginterferon alfa-2a

PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

DRUG

Ribavirin

Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients

Trial Locations (8)

2010

Kirketon Road Centre, Darlinghurst

St Vincent's Hospital, Darlinghurst

2050

Royal Prince Alfred Hospital, Camperdown

2751

Nepean Hospital, Penrith

3004

Alfred Hospital, Melbourne

3065

St Vincent's Hospital Melbourne, Melbourne

Royal Melbourne Hospital, Parkville

5000

Royal Adelaide Hospital, Adelaide